Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REBECCA L MOROOSE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1972503159
CMS profile
362319
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$157,739.91

136 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $89,594.98 96
Gilead Sciences, Inc. $68,032.22 39
Ethicon Inc. $112.71 1

Page 1 of 3; records 1–50 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REBECCA L MOROOSE

NPI 1972503159 · CMS profile ID 362319

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972503159?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972503159?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972503159?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1972503159?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

136 matching records · $157,739.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 136 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 136.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $2,000.0012/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918231859 CMS
Lilly USA, LLC $3,200.0012/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918261283 CMS
Lilly USA, LLC $1,148.1012/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918226937 CMS
Lilly USA, LLC $118.7512/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918261285 CMS
Lilly USA, LLC $1,600.0012/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918235219 CMS
Lilly USA, LLC $1,600.0012/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918261281 CMS
Lilly USA, LLC $20.0010/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918231857 CMS
Lilly USA, LLC $22.5010/25/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918261279 CMS
Lilly USA, LLC $15.0010/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918267805 CMS
Lilly USA, LLC $3,200.0010/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918231855 CMS
Lilly USA, LLC $2,800.0010/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918276159 CMS
Lilly USA, LLC $554.2010/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918202771 CMS
Lilly USA, LLC $186.5110/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918231845 CMS
Lilly USA, LLC $471.8310/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918231847 CMS
Lilly USA, LLC $15.5610/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918254553 CMS
Lilly USA, LLC $189.5210/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918276149 CMS
Gilead Sciences, Inc. $6,720.0010/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929441953 CMS
Gilead Sciences, Inc. $1,191.2410/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929470011 CMS
Gilead Sciences, Inc. $6,720.0009/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929441949 CMS
Gilead Sciences, Inc. $231.4409/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929469957 CMS
Gilead Sciences, Inc. $339.2809/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929469967 CMS
Gilead Sciences, Inc. $535.3409/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929469973 CMS
Lilly USA, LLC $1,600.0009/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918276157 CMS
Ethicon Inc. $112.7109/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887016243 CMS
Gilead Sciences, Inc. $6,720.0008/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929441945 CMS
Lilly USA, LLC $7.0008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918276155 CMS
Gilead Sciences, Inc. $22.5008/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929469939 CMS
Gilead Sciences, Inc. $186.4508/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929469951 CMS
Gilead Sciences, Inc. $604.2008/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929469993 CMS
Gilead Sciences, Inc. $1,008.2208/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929470005 CMS
Gilead Sciences, Inc. $80.0008/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929577389 CMS
Lilly USA, LLC $21.0007/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918231853 CMS
Lilly USA, LLC $22.5007/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918267803 CMS
Lilly USA, LLC $3,200.0007/18/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918235217 CMS
Lilly USA, LLC $2,800.0007/18/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918276153 CMS
Lilly USA, LLC $119.3407/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918202785 CMS
Lilly USA, LLC $10.5307/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918226947 CMS
Lilly USA, LLC $335.9807/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918231843 CMS
Lilly USA, LLC $311.4407/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918235205 CMS
Lilly USA, LLC $15.0007/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918261277 CMS
Lilly USA, LLC $20.0007/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918267801 CMS
Lilly USA, LLC $617.9207/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918276145 CMS
Lilly USA, LLC $2,800.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918254551 CMS
Lilly USA, LLC $3,200.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918276151 CMS
Lilly USA, LLC $125.3906/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918231839 CMS
Lilly USA, LLC $133.9806/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918235203 CMS
Lilly USA, LLC $152.9306/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918254541 CMS
Lilly USA, LLC $152.6706/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918261259 CMS
Lilly USA, LLC $626.0506/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918261261 CMS
Lilly USA, LLC $125.0006/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918261275 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $144,632.89 194
PY2020 $112,144.11 149
PY2021 $126,523.25 106
PY2022 $157,739.91 136
PY2023 $1,619.58 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,773.40 2
PY2025 Principal investigator $23,429.00 2
PY2024 Recipient $3,047.65 1
PY2023 Recipient $4,115.87 1
PY2023 Principal investigator $488.00 1
PY2022 Principal investigator $30,225.68 18
PY2021 Recipient $3,820.00 2
PY2021 Principal investigator $107,576.56 28
PY2020 Principal investigator $105,271.83 68
PY2019 Principal investigator $147,188.91 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 MEDIVATION INC. $431.00 12/15/2022 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 949770107
Principal investigator 1 MEDIVATION INC. $1,148.00 12/15/2022 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 949770109
Principal investigator 1 MEDIVATION INC. $1,148.00 12/15/2022 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 949770119
Principal investigator 1 MEDIVATION INC. $1,148.00 12/15/2022 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 949770121
Principal investigator 1 MEDIVATION INC. $1,085.00 12/15/2022 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 949770123
Principal investigator 1 MEDIVATION INC. $3.00 12/13/2022 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 949770387
Principal investigator 1 MEDIVATION INC. $973.00 12/07/2022 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 949770125
Principal investigator 1 PFIZER INC. $244.00 11/22/2022 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 949695285
Principal investigator 1 PFIZER INC. $9,582.00 06/16/2022 Non-covered Recipient Entity
TRIO US INC
A PHASE I OPENLABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB MDV3800 IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT No dispute reported 06/30/2026 949694509
Principal investigator 1 PFIZER INC. $2,650.00 05/25/2022 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 949695297
Principal investigator 1 Seagen Inc. $2,000.00 05/24/2022 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917884411
Principal investigator 1 Seagen Inc. $2,000.00 05/24/2022 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917884519
Principal investigator 1 Seagen Inc. $2,000.00 05/24/2022 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917884525
Principal investigator 1 Seagen Inc. $794.00 03/24/2022 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917884417
Principal investigator 1 Seagen Inc. $200.00 03/24/2022 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917884423
Principal investigator 1 Seagen Inc. $1,506.00 03/24/2022 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917884428
Principal investigator 1 Seagen Inc. $3,250.00 02/23/2022 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 917884335
Principal investigator 1 Novartis Pharmaceuticals Corporation $63.68 01/11/2022 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE No dispute reported 06/30/2026 909422844